US6238891B1
(en)
|
1987-11-18 |
2001-05-29 |
Cetus Oncology Corporation |
Method of increasing product expression through solute stress
|
CA1312030C
(en)
*
|
1987-11-18 |
1992-12-29 |
Brian Maiorella |
Method to increase antibody titer
|
US6048728A
(en)
*
|
1988-09-23 |
2000-04-11 |
Chiron Corporation |
Cell culture medium for enhanced cell growth, culture longevity, and product expression
|
AU632065B2
(en)
*
|
1988-09-23 |
1992-12-17 |
Novartis Vaccines And Diagnostics, Inc. |
Cell culture medium for enhanced cell growth, culture longevity and product expression
|
GB9004390D0
(en)
*
|
1990-02-27 |
1990-04-25 |
Ici Plc |
Process
|
US5122469A
(en)
*
|
1990-10-03 |
1992-06-16 |
Genentech, Inc. |
Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
|
GB9022545D0
(en)
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Culture medium
|
ES2053410T1
(es)
*
|
1991-06-17 |
1994-08-01 |
Life Technologies Inc |
Metodo para la preparacion de un medio de cultivo de celulas.
|
GB9118664D0
(en)
*
|
1991-08-30 |
1991-10-16 |
Celltech Ltd |
Cell culture
|
AU664469B2
(en)
|
1992-06-03 |
1995-11-16 |
Genentech Inc. |
Tissue plasminogen activator glycosylation variants with improved therapeutic properties
|
GB9215834D0
(en)
|
1992-07-24 |
1992-09-09 |
Celltech Ltd |
Cell culture
|
USH1532H
(en)
*
|
1993-11-03 |
1996-05-07 |
Genetics Institute, Inc. |
Adaption of mammalian cell lines to high cell densities
|
US5856179A
(en)
|
1994-03-10 |
1999-01-05 |
Genentech, Inc. |
Polypeptide production in animal cell culture
|
US5877016A
(en)
|
1994-03-18 |
1999-03-02 |
Genentech, Inc. |
Human trk receptors and neurotrophic factor inhibitors
|
US5708142A
(en)
|
1994-05-27 |
1998-01-13 |
Genentech, Inc. |
Tumor necrosis factor receptor-associated factors
|
US5705364A
(en)
|
1995-06-06 |
1998-01-06 |
Genentech, Inc. |
Mammalian cell culture process
|
US5830761A
(en)
*
|
1995-06-07 |
1998-11-03 |
Genetics Institute, Inc. |
Medium and methods for culturing mammalian cho cells
|
US5851984A
(en)
*
|
1996-08-16 |
1998-12-22 |
Genentech, Inc. |
Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
|
US6159462A
(en)
*
|
1996-08-16 |
2000-12-12 |
Genentech, Inc. |
Uses of Wnt polypeptides
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
DK0942992T3
(da)
|
1997-01-31 |
2007-07-02 |
Genentech Inc |
O-fucosyltransferase
|
PT1325932E
(pt)
|
1997-04-07 |
2005-06-30 |
Genentech Inc |
Anticorpos anti-vegf
|
WO1998045332A2
(en)
|
1997-04-07 |
1998-10-15 |
Genentech, Inc. |
Humanized antibodies and methods for forming humanized antibodies
|
US6342220B1
(en)
|
1997-08-25 |
2002-01-29 |
Genentech, Inc. |
Agonist antibodies
|
US6030619A
(en)
|
1997-08-27 |
2000-02-29 |
Chiron Corporation |
Molecular mimetics of meningococcal B epitopes
|
US6528286B1
(en)
|
1998-05-29 |
2003-03-04 |
Genentech, Inc. |
Mammalian cell culture process for producing glycoproteins
|
JP2002527066A
(ja)
|
1998-10-15 |
2002-08-27 |
カイロン コーポレイション |
転移性乳癌および結腸癌調節遺伝子
|
EP1950300A3
(de)
|
1998-11-18 |
2011-03-23 |
Genentech, Inc. |
Antikörpervarianten mit höherer Bindungsaffinität im Vergleich zu verwandten Antikörpern
|
PT1141331E
(pt)
|
1998-12-16 |
2008-12-22 |
Novartis Vaccines & Diagnostic |
Quinase dependente de ciclina humana (hpnqalre)
|
KR101077001B1
(ko)
|
1999-01-15 |
2011-10-26 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
EP1171615B1
(de)
|
1999-04-26 |
2006-12-13 |
Genentech, Inc. |
Zellenzuchtverfahren für glycoproteine
|
ATE437655T1
(de)
|
1999-06-25 |
2009-08-15 |
Genentech Inc |
Humanisierte anti-erbb2 antikörper und behandlung mit anti-erbb2 antikörper
|
AU783767B2
(en)
|
1999-10-14 |
2005-12-01 |
Takara Bio Usa, Inc. |
Anthozoa derived chromophores/fluorophores and methods for using the same
|
DE60030323T2
(de)
|
1999-12-24 |
2007-10-11 |
Genentech, Inc., South San Francisco |
Verfahren und verbindungen zur verlängerung der halbwertzeiten bei der ausscheidung von biowirksamen verbindungen
|
EP1757311B1
(de)
|
1999-12-24 |
2009-02-11 |
Genentech, Inc. |
Verfahren und Zusammensetzungen zur Verlängerung der Entsorgungshalbwertszeit von biowirksamen Verbindungen
|
ATE402258T1
(de)
|
2000-01-10 |
2008-08-15 |
Novartis Vaccines & Diagnostic |
Gene differentiell experimiert in brudtkrebs
|
EP1272647B1
(de)
|
2000-04-11 |
2014-11-12 |
Genentech, Inc. |
Multivalente antikörper und deren verwendung
|
CA2413156C
(en)
|
2000-07-03 |
2009-08-18 |
Gala Design, Inc. |
Expression vectors
|
US6852510B2
(en)
|
2000-07-03 |
2005-02-08 |
Gala Design Inc |
Host cells containing multiple integrating vectors
|
PT1303293E
(pt)
|
2000-07-27 |
2009-03-11 |
Genentech Inc |
Administração sequencial de cpt-11 e polipéptido apo-2l
|
US7087726B2
(en)
|
2001-02-22 |
2006-08-08 |
Genentech, Inc. |
Anti-interferon-α antibodies
|
WO2002081642A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc-3 and diagnostic and therapeutic uses thereof
|
WO2002081639A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene brcc2 and diagnostic and therapeutic uses thereof
|
WO2002081641A2
(en)
|
2001-04-06 |
2002-10-17 |
Georgetown University |
Gene scc-112 and diagnostic and therapeutic uses thereof
|
KR100607612B1
(ko)
|
2001-06-20 |
2006-08-02 |
제넨테크, 인크. |
종양의 진단 및 치료를 위한 방법 및 이를 위한 조성물
|
WO2003018771A2
(en)
|
2001-08-27 |
2003-03-06 |
Genentech, Inc. |
A system for antibody expression and assembly
|
PL368972A1
(en)
|
2001-08-29 |
2005-04-04 |
Genentech, Inc. |
Bv8 nucleic acids and polypeptides with mitogenic activity
|
EP2153843B1
(de)
|
2001-09-18 |
2012-08-15 |
Genentech, Inc. |
Zusammensetzungen und Verfahren zur Behandlung und Diagnose von Tumoren
|
WO2003054158A2
(en)
|
2001-12-19 |
2003-07-03 |
The University Of Chicago |
Rapidly maturing fluorescent proteins and methods for using the same
|
US20030228305A1
(en)
|
2002-01-02 |
2003-12-11 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
US20040038304A1
(en)
|
2002-03-28 |
2004-02-26 |
Gala Design, Inc. |
Antibody libraries
|
US7384738B2
(en)
|
2002-03-28 |
2008-06-10 |
Bremel Robert D |
Retrovirus-based genomic screening
|
US7244565B2
(en)
|
2002-04-10 |
2007-07-17 |
Georgetown University |
Gene shinc-3 and diagnostic and therapeutic uses thereof
|
US7138512B2
(en)
|
2002-04-10 |
2006-11-21 |
Georgetown University |
Gene SHINC-2 and diagnostic and therapeutic uses thereof
|
EP1571968A4
(de)
|
2002-04-16 |
2007-10-17 |
Genentech Inc |
Zusammensetzungen und verfahren zur diagnose und behandlung von tumoren
|
JP2005528905A
(ja)
|
2002-06-07 |
2005-09-29 |
ジェネンテック・インコーポレーテッド |
腫瘍の診断と治療のための組成物と方法
|
ES2376165T3
(es)
|
2002-07-15 |
2012-03-09 |
F. Hoffmann-La Roche Ag |
Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
|
DK2332996T3
(en)
|
2002-09-11 |
2014-12-15 |
Genentech Inc |
Purification of anti-Her2 antibodies
|
WO2004065417A2
(en)
|
2003-01-23 |
2004-08-05 |
Genentech, Inc. |
Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
|
JP4912144B2
(ja)
|
2003-03-12 |
2012-04-11 |
ジェネンテック, インコーポレイテッド |
造血促進のためのbv8及び/又はeg−vegfの使用
|
KR20180014881A
(ko)
|
2003-05-30 |
2018-02-09 |
제넨테크, 인크. |
항-vegf 항체를 사용한 치료
|
US20050106667A1
(en)
|
2003-08-01 |
2005-05-19 |
Genentech, Inc |
Binding polypeptides with restricted diversity sequences
|
SI2161283T1
(sl)
|
2003-11-17 |
2014-10-30 |
Genentech, Inc. |
Sestavki, ki obsegajo protitelesa proti CD79b, konjugirana na sredstvo, ki inhibira rast, ali na citotoksično sredstvo, in postopki za zdravljenje tumorja hematopoetskega izvora
|
BRPI0417107A
(pt)
|
2003-12-19 |
2007-02-06 |
Genentech Inc |
fragmento de anticorpo, métodos de preparação do fragmento de anticorpo, ácido nucléico isolado, composições, célula hospedeira e métodos de fabricação e de geração de fragmento de anticorpo
|
TR201815885T4
(tr)
|
2004-01-07 |
2018-11-21 |
Novartis Vaccines & Diagnostics Inc |
M-csf spesifik monoklonal antikorlar ve bunların kullanımı.
|
JP2007528784A
(ja)
|
2004-02-11 |
2007-10-18 |
マサチューセッツ・インスティチュート・オブ・テクノロジー |
多層ポリマー被覆磁性ナノクラスタ
|
US8268324B2
(en)
|
2004-03-29 |
2012-09-18 |
Galpharma Co., Ltd. |
Modified galectin 9 proteins and use thereof
|
US7794713B2
(en)
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
WO2005100387A1
(en)
|
2004-04-07 |
2005-10-27 |
The University Of Chicago |
Monomeric red fluorescent proteins
|
US20150017671A1
(en)
|
2004-04-16 |
2015-01-15 |
Yaping Shou |
Methods for detecting lp-pla2 activity and inhibition of lp-pla2 activity
|
WO2005108424A1
(en)
|
2004-05-06 |
2005-11-17 |
Genentech, Inc. |
Crystal structure of the complex of hepatocyte growth factor bata chain with met receptor and methods of use
|
EP2361931B1
(de)
|
2004-07-20 |
2017-12-06 |
Genentech, Inc. |
Angiopoietin-like 4 Protein Hemmer Kombinationen und deren Verwendung
|
US7597884B2
(en)
|
2004-08-09 |
2009-10-06 |
Alios Biopharma, Inc. |
Hyperglycosylated polypeptide variants and methods of use
|
KR101364276B1
(ko)
|
2004-09-03 |
2014-02-20 |
제넨테크, 인크. |
인간화 항-베타7 길항제 및 그의 용도
|
US7741096B2
(en)
|
2004-12-10 |
2010-06-22 |
Genentech, Inc. |
Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor
|
EP2230517A1
(de)
|
2005-01-07 |
2010-09-22 |
Diadexus, Inc. |
OVR110-Antikörperzusammensetzungen und Verwendungsverfahren dafür
|
US8029783B2
(en)
|
2005-02-02 |
2011-10-04 |
Genentech, Inc. |
DR5 antibodies and articles of manufacture containing same
|
NZ561681A
(en)
|
2005-03-21 |
2011-01-28 |
Virobay Inc |
Alpha ketoamide compounds as cysteine protease inhibitors
|
EP1869230B1
(de)
|
2005-03-23 |
2017-08-30 |
Bio-Rad Laboratories, Inc. |
Verfahren zur reinigung von proteinen
|
ATE515512T1
(de)
|
2005-05-12 |
2011-07-15 |
Zymogenetics Inc |
Zusammensetzungen und verfahren zur modulierung von immunreaktionen
|
EP1913027B1
(de)
|
2005-07-28 |
2015-03-04 |
Novartis AG |
M-csf-spezifische monoklonale antikörper und anwendungen davon
|
EP3181575B1
(de)
|
2005-08-31 |
2021-03-17 |
The Regents of The University of California |
Zelluläre peptidsequenzbibliotheken (clips) und verfahren zur verwendung davon
|
US7749704B2
(en)
|
2005-11-01 |
2010-07-06 |
Mayo Foundation For Medical Education And Research |
Promoter polymorphisms of the BLyS gene and use in diagnostic methods
|
WO2007056441A2
(en)
|
2005-11-07 |
2007-05-18 |
Genentech, Inc. |
Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
SI1948798T1
(sl)
|
2005-11-18 |
2015-09-30 |
Glenmark Pharmaceuticals S.A. |
Anti-alfa 2 integrin protitelesa in njihova uporaba
|
EP1957540B1
(de)
|
2005-12-02 |
2012-06-13 |
Genentech, Inc. |
Bindungspolypeptide und verwendung davon
|
CN105859886A
(zh)
|
2005-12-02 |
2016-08-17 |
健泰科生物技术公司 |
牵涉与il-22和il-22r结合的抗体的组合物和方法
|
JP5358187B2
(ja)
|
2005-12-15 |
2013-12-04 |
ジェネンテック, インコーポレイテッド |
ポリユビキチンを標的とする方法と組成物
|
DK1973950T3
(en)
|
2006-01-05 |
2014-12-15 |
Genentech Inc |
ANTI-EphB4 ANTIBODIES AND METHODS FOR USING SAME
|
AR059851A1
(es)
|
2006-03-16 |
2008-04-30 |
Genentech Inc |
Anticuerpos de la egfl7 y metodos de uso
|
WO2007109376A2
(en)
|
2006-03-23 |
2007-09-27 |
Novartis Ag |
Anti-tumor cell antigen antibody therapeutics
|
KR20140071452A
(ko)
|
2006-04-05 |
2014-06-11 |
애브비 바이오테크놀로지 리미티드 |
항체 정제
|
TWI395754B
(zh)
|
2006-04-24 |
2013-05-11 |
Amgen Inc |
人類化之c-kit抗體
|
WO2007127936A2
(en)
|
2006-04-27 |
2007-11-08 |
Pikamab, Inc. |
Methods and compositions for antibody therapy
|
EP2446904B1
(de)
|
2006-05-30 |
2015-04-29 |
Genentech, Inc. |
Anti-CD22 Antikörper, Immunkonjugate sowie ihre Verwendungen
|
US7862812B2
(en)
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
ES2531933T3
(es)
|
2006-06-30 |
2015-03-20 |
Novo Nordisk A/S |
Anticuerpos anti-NKG2A y usos de los mismos
|
WO2008013943A2
(en)
*
|
2006-07-27 |
2008-01-31 |
Wyeth |
High-cell density fed-batch fermentation process for producing recombinant protein
|
EP2420252A1
(de)
|
2006-08-04 |
2012-02-22 |
Novartis AG |
EPHB3-spezifischer Antikörper und Verwendungen davon
|
CA2661023C
(en)
|
2006-08-18 |
2017-08-15 |
Novartis Ag |
Prlr-specific antibody and uses thereof
|
US8623830B2
(en)
|
2006-09-12 |
2014-01-07 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions containing α-1-antitrypsin and methods for use
|
US7985783B2
(en)
|
2006-09-21 |
2011-07-26 |
The Regents Of The University Of California |
Aldehyde tags, uses thereof in site-specific protein modification
|
CA2667706A1
(en)
|
2006-10-27 |
2008-05-08 |
Lpath, Inc. |
Compositions and methods for treating ocular diseases and conditions
|
RU2460541C2
(ru)
|
2006-10-27 |
2012-09-10 |
Лпат, Инк. |
Композиции и способы связывания сфингозин-1-фосфата
|
ES2636089T3
(es)
|
2006-10-27 |
2017-10-05 |
Genentech, Inc. |
Anticuerpos e inmunoconjugados y usos para los mismos
|
MX2009004757A
(es)
|
2006-11-14 |
2009-05-21 |
Genentech Inc |
Moduladores de regeneracion neuronal.
|
US8470332B2
(en)
|
2006-11-22 |
2013-06-25 |
Bristol-Myers Squibb Company |
Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
|
WO2008067283A2
(en)
|
2006-11-27 |
2008-06-05 |
Diadexus, Inc. |
Ovr110 antibody compositions and methods of use
|
EA200900767A1
(ru)
|
2006-12-07 |
2009-12-30 |
Новартис Аг |
Антагонистические антитела против ephb3
|
AU2008204335B2
(en)
|
2007-01-11 |
2013-06-13 |
Michael Bacher |
Diagnosis and treatment of Alzheimer's and other neurodementing diseases
|
ATE526017T1
(de)
|
2007-01-22 |
2011-10-15 |
Genentech Inc |
Abscheidung von polyelektrolyten und reinigung von antikörpern
|
US20100144599A1
(en)
|
2007-02-02 |
2010-06-10 |
Bristol-Myers Squibb Company |
Vegf pathway blockade
|
WO2008100805A2
(en)
|
2007-02-09 |
2008-08-21 |
Genentech, Inc. |
Anti-robo4 antibodies and uses therefor
|
WO2008103962A2
(en)
|
2007-02-22 |
2008-08-28 |
Genentech, Inc. |
Methods for detecting inflammatory bowel disease
|
US7960139B2
(en)
|
2007-03-23 |
2011-06-14 |
Academia Sinica |
Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
|
ES2687270T3
(es)
|
2007-04-12 |
2018-10-24 |
The Brigham And Women's Hospital, Inc. |
Fijación como objetivo de ABCB5 para la terapia del cáncer
|
US9163091B2
(en)
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
EP2164992B1
(de)
|
2007-05-30 |
2016-05-04 |
Lpath, Inc. |
Zusammensetzungen und verfahren zur bindung von lysophosphatidinsäure
|
CA2690124A1
(en)
|
2007-06-07 |
2008-12-18 |
Genentech, Inc. |
C3b antibodies and methods for the prevention and treatment of complement-associated disorders
|
LT3597659T
(lt)
|
2007-07-09 |
2023-05-10 |
Genentech, Inc. |
Disulfidinės jungties redukcijos prevencijos būdas gaminant polipeptidą rekombinantiniu būdu
|
CN111499748A
(zh)
|
2007-07-16 |
2020-08-07 |
健泰科生物技术公司 |
抗cd79b抗体和免疫偶联物及使用方法
|
PE20090481A1
(es)
|
2007-07-16 |
2009-05-18 |
Genentech Inc |
Anticuerpos anti-cd79b e inmunoconjugados humanizados y metodos de uso
|
JP5734653B2
(ja)
|
2007-09-05 |
2015-06-17 |
ジェネンテック, インコーポレイテッド |
生物学的に活性なc末端アルギニン含有ペプチド
|
AU2008308509B2
(en)
|
2007-10-04 |
2014-10-23 |
Zymogenetics, Inc. |
B7 family member zB7H6 and related compositions and methods
|
SI2215117T2
(en)
|
2007-10-30 |
2018-04-30 |
Genentech, Inc. |
Purification of the antibody by cation exchange chromatography
|
US8679749B2
(en)
|
2007-11-01 |
2014-03-25 |
The University Of Chicago |
Red fluorescent proteins with enhanced bacterial expression, increased brightness and reduced aggregation
|
CA2705007A1
(en)
|
2007-11-07 |
2009-05-14 |
Genentech, Inc. |
Compositions and methods for treatment of microbial disorders
|
JP2011503094A
(ja)
|
2007-11-08 |
2011-01-27 |
ジェネンテック, インコーポレイテッド |
抗b因子抗体およびそれらの使用
|
TWI580694B
(zh)
|
2007-11-30 |
2017-05-01 |
建南德克公司 |
抗-vegf抗體
|
US8003325B2
(en)
|
2007-11-30 |
2011-08-23 |
Mayo Foundation For Medical Education And Research |
Polymorphisms of the BLyS gene and use in diagnostic methods
|
EP2261254A3
(de)
|
2007-12-21 |
2011-04-13 |
Amgen, Inc |
Antiamyloide Antikörper und deren Verwendungen
|
AR070141A1
(es)
|
2008-01-23 |
2010-03-17 |
Glenmark Pharmaceuticals Sa |
Anticuerpos humanizados especificos para el factor von willebrand
|
WO2009092805A1
(en)
|
2008-01-24 |
2009-07-30 |
Novo Nordisk A/S |
Humanized anti-human nkg2a monoclonal antibody
|
US9175078B2
(en)
|
2008-01-25 |
2015-11-03 |
Amgen Inc. |
Ferroportin antibodies and methods of use
|
EP3269737B1
(de)
|
2008-01-31 |
2024-06-19 |
Genentech, Inc. |
Anti-cd79b-antikörper und immunkonjugate sowie verfahren zur verwendung
|
ES2487846T3
(es)
|
2008-05-01 |
2014-08-25 |
Amgen, Inc. |
Anticuerpos anti-hepcindina y métodos de uso
|
AU2009244300B2
(en)
|
2008-05-06 |
2014-04-17 |
Genentech, Inc. |
Affinity matured CRIg variants
|
WO2009142773A2
(en)
|
2008-05-22 |
2009-11-26 |
Bristol-Myers Squibb Company |
Multivalent fibronectin based scaffold domain proteins
|
US8680020B2
(en)
|
2008-07-15 |
2014-03-25 |
Academia Sinica |
Glycan arrays on PTFE-like aluminum coated glass slides and related methods
|
LT2848625T
(lt)
|
2008-08-14 |
2019-10-10 |
Genentech, Inc. |
Priemaišų pašalinimo būdai, panaudojant reziduojančio baltymo pakeitimą jonų mainų membraninės chromatografijos pagalba
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
JP4883067B2
(ja)
|
2008-09-29 |
2012-02-22 |
株式会社日立プラントテクノロジー |
培養装置及び培養方法
|
EP2921501A1
(de)
|
2008-10-20 |
2015-09-23 |
Abbvie Inc. |
Isolation und Aufreinigung von Antikörpern mit Protein-A-Affinitätschromatografie
|
JP5851838B2
(ja)
|
2008-10-22 |
2016-02-03 |
ジェネンテック, インコーポレイテッド |
軸索変性の調節
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
AU2009312532B2
(en)
|
2008-11-06 |
2013-05-16 |
Ichnos Sciences SA |
Treatment with anti-alpha2 integrin antibodies
|
TWI496582B
(zh)
|
2008-11-24 |
2015-08-21 |
必治妥美雅史谷比公司 |
雙重專一性之egfr/igfir結合分子
|
EP4169951A1
(de)
|
2008-12-09 |
2023-04-26 |
F. Hoffmann-La Roche AG |
Anti-pd-l1-antikörper und deren verwendung zur verbesserung der t-zell-funktion
|
US10080578B2
(en)
|
2008-12-16 |
2018-09-25 |
Nico Corporation |
Tissue removal device with adjustable delivery sleeve for neurosurgical and spinal surgery applications
|
WO2010108153A2
(en)
|
2009-03-20 |
2010-09-23 |
Amgen Inc. |
Carrier immunoglobulins and uses thereof
|
HUE061117T2
(hu)
|
2009-03-25 |
2023-05-28 |
Genentech Inc |
Anti-FGFR3 antitestek és eljárások alkalmazásukra
|
JP6132548B2
(ja)
|
2009-04-01 |
2017-05-24 |
ジェネンテック, インコーポレイテッド |
抗FcRH5抗体および免疫接合体および使用方法
|
EP2414391B1
(de)
|
2009-04-02 |
2018-11-28 |
Roche Glycart AG |
Multispezifische antikörper, umfassend vollständige antikörper und einzelketten-fab-fragmente
|
US20100297127A1
(en)
|
2009-04-08 |
2010-11-25 |
Ghilardi Nico P |
Use of il-27 antagonists to treat lupus
|
JP2012533306A
(ja)
|
2009-07-15 |
2012-12-27 |
アボット・ラボラトリーズ |
機械的伝達による細胞産生の強化
|
US8765431B2
(en)
|
2009-07-23 |
2014-07-01 |
The Regents Of The University Of Michigan |
Method for enzymatic production of decarboxylated polyketides and fatty acids
|
MX2012001306A
(es)
|
2009-07-31 |
2012-02-28 |
Genentech Inc |
Inhibicion de matastasis de tumor.
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
RU2639288C2
(ru)
|
2009-08-11 |
2017-12-20 |
Дженентек, Инк. |
Получение белков в культуральных средах без глутамина
|
US20110053223A1
(en)
|
2009-08-14 |
2011-03-03 |
Robert Bayer |
Cell culture methods to make antibodies with enhanced adcc function
|
CN108409829A
(zh)
|
2009-09-01 |
2018-08-17 |
弗·哈夫曼-拉罗切有限公司 |
通过改进的a蛋白洗脱增强的蛋白质纯化
|
WO2011028950A1
(en)
|
2009-09-02 |
2011-03-10 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
RU2573915C2
(ru)
|
2009-09-16 |
2016-01-27 |
Дженентек, Инк. |
Содержащие суперспираль и/или привязку белковые комплексы и их применение
|
US9885711B2
(en)
|
2009-09-25 |
2018-02-06 |
Xoma Technology Ltd. |
Screening methods
|
US8926976B2
(en)
|
2009-09-25 |
2015-01-06 |
Xoma Technology Ltd. |
Modulators
|
EP2491058A1
(de)
|
2009-10-19 |
2012-08-29 |
F. Hoffmann-La Roche AG |
Modulatoren des hepatozytenwachstumsfaktoraktivators
|
MX2012004711A
(es)
|
2009-10-20 |
2012-05-23 |
Abbott Lab |
Aislamiento y purificacion de los anticuerpos anti-il-13 al usar cromatografia de afinidad con proteina a.
|
CN102711826B
(zh)
|
2009-10-22 |
2017-03-29 |
霍夫曼-拉罗奇有限公司 |
用于调控巨噬细胞刺激性蛋白的hepsin活化的方法和组合物
|
AU2010310589A1
(en)
|
2009-10-22 |
2012-05-10 |
Genentech, Inc. |
Modulation of axon degeneration
|
JP5814925B2
(ja)
|
2009-10-22 |
2015-11-17 |
ジェネンテック, インコーポレイテッド |
抗ヘプシン抗体及びその使用方法
|
WO2011056494A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
|
WO2011056497A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Activin receptor type iib compositions and methods of use
|
WO2011056502A1
(en)
|
2009-10-26 |
2011-05-12 |
Genentech, Inc. |
Bone morphogenetic protein receptor type ii compositions and methods of use
|
US20110098862A1
(en)
|
2009-10-27 |
2011-04-28 |
ExxonMobil Research Engineering Company Law Department |
Multi-stage processes and control thereof
|
US8524458B2
(en)
|
2009-11-09 |
2013-09-03 |
Abbvie Inc. |
Secretory protein biomarkers for high efficiency protein expression
|
WO2011060246A2
(en)
|
2009-11-12 |
2011-05-19 |
Genentech, Inc. |
A method of promoting dendritic spine density
|
AU2010321832B2
(en)
|
2009-11-20 |
2014-08-14 |
Amgen Inc. |
Anti-Orai1 antigen binding proteins and uses thereof
|
WO2011065940A1
(en)
|
2009-11-24 |
2011-06-03 |
Biogen Idec Ma Inc. |
Method of supplementing culture media to prevent undesirable amino acid substitutions
|
PE20121584A1
(es)
|
2009-11-30 |
2012-11-29 |
Genentech Inc |
Composiciones y metodos para el diagnostico y el tratamiento de tumores
|
US11377485B2
(en)
|
2009-12-02 |
2022-07-05 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US10087236B2
(en)
|
2009-12-02 |
2018-10-02 |
Academia Sinica |
Methods for modifying human antibodies by glycan engineering
|
US8486397B2
(en)
|
2009-12-11 |
2013-07-16 |
Genentech, Inc. |
Anti-VEGF-C antibodies and methods using same
|
CN102770158B
(zh)
|
2009-12-21 |
2016-10-19 |
霍夫曼-拉罗奇有限公司 |
抗体配制剂
|
AU2010336485B2
(en)
|
2009-12-23 |
2015-03-26 |
Genentech, Inc. |
Anti-Bv8 antibodies and uses thereof
|
AR080243A1
(es)
|
2010-02-23 |
2012-03-21 |
Genentech Inc |
Composiciones y metodos para el diagnostico y tratamiento de tumores
|
JP5972176B2
(ja)
|
2010-02-23 |
2016-08-17 |
サノフイ |
抗アルファ2インテグリン抗体及びそれらの使用
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
BR112012024713B1
(pt)
|
2010-03-31 |
2021-02-17 |
Boehringer Ingelheim International Gmbh |
anticorpo humanizado, seus usos e composição farmacêutica que o compreende
|
WO2011130332A1
(en)
|
2010-04-12 |
2011-10-20 |
Academia Sinica |
Glycan arrays for high throughput screening of viruses
|
WO2011133931A1
(en)
|
2010-04-22 |
2011-10-27 |
Genentech, Inc. |
Use of il-27 antagonists for treating inflammatory bowel disease
|
WO2011133886A2
(en)
|
2010-04-23 |
2011-10-27 |
Genentech, Inc. |
Production of heteromultimeric proteins
|
US20110262965A1
(en)
|
2010-04-23 |
2011-10-27 |
Life Technologies Corporation |
Cell culture medium comprising small peptides
|
RU2577972C2
(ru)
|
2010-04-26 |
2016-03-20 |
Новартис Аг |
Способ получения рекомбинантного полипептида
|
MA34291B1
(fr)
|
2010-05-03 |
2013-06-01 |
Genentech Inc |
Compositions et méthodes de diagnostic et de traitement d'une tumeur
|
TW201138808A
(en)
|
2010-05-03 |
2011-11-16 |
Bristol Myers Squibb Co |
Serum albumin binding molecules
|
EP2568976B1
(de)
|
2010-05-10 |
2015-09-30 |
Academia Sinica |
Zanamivir-phosphinat-kongenere mit antigrippewirkung und bestimmung der oseltamivir-empfänglichkeit von influenzaviren
|
EP2576615B1
(de)
|
2010-05-26 |
2016-03-30 |
Bristol-Myers Squibb Company |
Auf fibronectin basierende gerüstproteine mit erhöhter stabilität
|
MX343604B
(es)
|
2010-05-28 |
2016-11-11 |
Genentech Inc |
Disminuir nivel de lactato e incrementar producción de polipéptidos por regulación a la baja de la expresión de lactato dehidrogenasa y piruvato dehidrogenasa quinasa.
|
WO2011153346A1
(en)
|
2010-06-03 |
2011-12-08 |
Genentech, Inc. |
Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
|
BR112012032206A2
(pt)
|
2010-06-16 |
2016-10-04 |
Abbvie Inc |
comparações de amostras de proteínas
|
EP2590654B1
(de)
|
2010-07-09 |
2016-12-21 |
Exelixis, Inc. |
Kombinationen aus kinasehemmern zur behandlung von krebs
|
WO2012021648A1
(en)
|
2010-08-10 |
2012-02-16 |
Amgen Inc. |
Dual function in vitro target binding assay for the detection of neutralizing antibodies against target antibodies
|
EP2603525A1
(de)
|
2010-08-13 |
2013-06-19 |
F.Hoffmann-La Roche Ag |
Antikörper gegen il-1beta und il-18 zur behandlung von krankheiten
|
BR112013001847A2
(pt)
|
2010-08-24 |
2016-05-31 |
Hoffmann La Roche |
anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
|
RU2608499C2
(ru)
|
2010-09-20 |
2017-01-18 |
Эббви Инк. |
Очистка антител с помощью хроматографии с псевдодвижущимся слоем
|
CN103339145A
(zh)
|
2010-09-22 |
2013-10-02 |
安姆根有限公司 |
运载体免疫球蛋白及其用途
|
AU2011312205B2
(en)
|
2010-10-05 |
2015-08-13 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
KR101631740B1
(ko)
|
2010-10-08 |
2016-06-17 |
상하이 켁신 바이오테크 씨오., 엘티디. |
모에신 단편의 진단학적 및 치료학적 용도
|
CA2814023C
(en)
|
2010-10-08 |
2018-01-16 |
Shanghai Kexin Biotech Co., Ltd. |
Moesin fragments and uses thereof
|
KR101687060B1
(ko)
|
2010-10-08 |
2016-12-15 |
상하이 켁신 바이오테크 씨오., 엘티디. |
모에신 조절제 및 그의 용도
|
JP5868410B2
(ja)
|
2010-10-08 |
2016-02-24 |
シャンハイ クーシン バイオテック カンパニー,リミテッド |
再生不良性貧血と関連しているモエシン断片
|
EP2624856B1
(de)
|
2010-10-08 |
2016-12-14 |
Shanghai Kexin Biotech Co., Ltd |
Moesinfragmente zur verwendung zur diagnose von immun-thrombozytopenie
|
RS55161B1
(sr)
|
2010-11-04 |
2017-01-31 |
Boehringer Ingelheim Int |
Anti-il-23 antitela
|
SG10201407036YA
(en)
|
2010-11-05 |
2014-12-30 |
Transbio Ltd |
Markers of Endothelial Progenitor Cells and Uses Thereof
|
EP2640367A2
(de)
|
2010-11-15 |
2013-09-25 |
Exelixis, Inc. |
Benzoxazepine als pi3k/mtor-hemmer sowie verfahren zur ihrer verwendung und herstellung
|
EP2640366A2
(de)
|
2010-11-15 |
2013-09-25 |
Exelixis, Inc. |
Benzoxazepine als pi3k/mtor-hemmer sowie verfahren zur ihrer verwendung und herstellung
|
EP2643316A2
(de)
|
2010-11-24 |
2013-10-02 |
Exelixis, Inc. |
Benzoxazepine als p13k/mtor-hemmer sowie verfahren zur ihrer verwendung und herstellung
|
WO2012083370A1
(en)
|
2010-12-22 |
2012-06-28 |
Cephalon Australia Pty Ltd |
Modified antibody with improved half-life
|
SG191153A1
(en)
|
2010-12-23 |
2013-07-31 |
Hoffmann La Roche |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
WO2012092539A2
(en)
|
2010-12-31 |
2012-07-05 |
Takeda Pharmaceutical Company Limited |
Antibodies to dll4 and uses thereof
|
KR20140009311A
(ko)
|
2011-01-18 |
2014-01-22 |
암젠 인크 |
Nav1.7 넉아웃 마우스 및 이의 용도
|
CA2825064C
(en)
|
2011-02-04 |
2022-08-30 |
Genentech, Inc. |
Fc variants and methods for their production
|
US10689447B2
(en)
|
2011-02-04 |
2020-06-23 |
Genentech, Inc. |
Fc variants and methods for their production
|
WO2012122528A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Bispecific three-chain antibody-like molecules
|
WO2012122512A1
(en)
|
2011-03-10 |
2012-09-13 |
Hco Antibody, Inc. |
Recombinant production of mixtures of single chain antibodies
|
WO2012125735A1
(en)
|
2011-03-15 |
2012-09-20 |
Abott Laboratories |
An integrated approach to the isolation and purification of antibodies
|
EP2689250A1
(de)
|
2011-03-23 |
2014-01-29 |
AbbVie Inc. |
Verfahren und systeme zur analyse von proteinproben
|
WO2012135589A1
(en)
|
2011-03-31 |
2012-10-04 |
Genentech, Inc. |
Methods of administering beta7 integrin antagonists
|
WO2012149197A2
(en)
|
2011-04-27 |
2012-11-01 |
Abbott Laboratories |
Methods for controlling the galactosylation profile of recombinantly-expressed proteins
|
EP2714735B1
(de)
|
2011-06-03 |
2021-07-21 |
XOMA Technology Ltd. |
Tgf-beta-spezifische antikörper
|
JP2013040160A
(ja)
|
2011-07-01 |
2013-02-28 |
Genentech Inc |
自己免疫疾患を治療するための抗cd83アゴニスト抗体の使用
|
WO2013025944A1
(en)
|
2011-08-17 |
2013-02-21 |
Genentech, Inc. |
Inhibition of angiogenesis in refractory tumors
|
CN104093744A
(zh)
|
2011-10-11 |
2014-10-08 |
弗·哈夫曼-拉罗切有限公司 |
双特异性抗体的改进的组装
|
JP2015504038A
(ja)
|
2011-10-31 |
2015-02-05 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
低減した免疫原性を有するフィブロネクチン結合ドメイン
|
KR20200110476A
(ko)
|
2011-11-16 |
2020-09-23 |
베링거 인겔하임 인터내셔날 게엠베하 |
항 il-36r 항체
|
CA2857168C
(en)
|
2011-12-01 |
2020-10-27 |
Protevobio, Inc. |
Protein inhibitors to complement and vegf pathways and methods of use thereof
|
JP6415326B2
(ja)
|
2011-12-16 |
2018-10-31 |
ブラスケム エス.エー. |
改変された微生物およびそれを用いてブタジエンを作製する方法
|
WO2013091903A1
(en)
|
2011-12-22 |
2013-06-27 |
Novo Nordisk A/S |
Anti-crac channel antibodies
|
SG11201403437TA
(en)
|
2011-12-22 |
2014-07-30 |
Genentech Inc |
Ion exchange membrane chromatography
|
US20150011431A1
(en)
|
2012-01-09 |
2015-01-08 |
The Scripps Research Institute |
Humanized antibodies
|
CN104520321A
(zh)
|
2012-01-09 |
2015-04-15 |
斯克利普斯研究所 |
超长互补决定区及其用途
|
WO2013116287A1
(en)
|
2012-01-31 |
2013-08-08 |
Genentech, Inc. |
Anti-ig-e m1' antibodies and methods using same
|
EP2812357B1
(de)
|
2012-02-10 |
2020-11-04 |
F.Hoffmann-La Roche Ag |
Einzelketten-antikörper und andere heteromultimere
|
EP2816893A1
(de)
|
2012-02-22 |
2014-12-31 |
Amgen Inc. |
Aus induzierten pluripotenten stammzellen gewonnene autologe säugetiere und entsprechende verfahren
|
US9493744B2
(en)
|
2012-06-20 |
2016-11-15 |
Genentech, Inc. |
Methods for viral inactivation and other adventitious agents
|
US10130714B2
(en)
|
2012-04-14 |
2018-11-20 |
Academia Sinica |
Enhanced anti-influenza agents conjugated with anti-inflammatory activity
|
WO2013158273A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Methods to modulate c-terminal lysine variant distribution
|
WO2013158275A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Cell culture methods to reduce acidic species
|
US9067990B2
(en)
|
2013-03-14 |
2015-06-30 |
Abbvie, Inc. |
Protein purification using displacement chromatography
|
WO2013158279A1
(en)
|
2012-04-20 |
2013-10-24 |
Abbvie Inc. |
Protein purification methods to reduce acidic species
|
US20130281355A1
(en)
|
2012-04-24 |
2013-10-24 |
Genentech, Inc. |
Cell culture compositions and methods for polypeptide production
|
DK2841087T3
(da)
|
2012-04-27 |
2017-11-20 |
Us Health |
Vaskulær endothel-vækstfaktor-antagonister og fremgangsmåder til anvendelse deraf
|
EP2844284A1
(de)
|
2012-05-03 |
2015-03-11 |
Boehringer Ingelheim International GmbH |
Anti-il-23p19-antikörper
|
US20140010820A1
(en)
|
2012-05-21 |
2014-01-09 |
Abbvie, Inc. |
Novel purification of non-human antibodies using protein a affinity chromatography
|
US9249182B2
(en)
|
2012-05-24 |
2016-02-02 |
Abbvie, Inc. |
Purification of antibodies using hydrophobic interaction chromatography
|
JP6203838B2
(ja)
|
2012-06-27 |
2017-09-27 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
少なくとも2つの異なる結合実体を含む、テーラーメイドの高度に選択的かつ多重特異的なターゲティング実体を選択および作製するための方法、ならびにその使用
|
WO2014001326A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
CA2880701A1
(en)
|
2012-08-18 |
2014-02-27 |
Academia Sinica |
Cell-permeable probes for identification and imaging of sialidases
|
AU2013305827A1
(en)
|
2012-08-21 |
2015-03-05 |
Academia Sinica |
Benzocyclooctyne compounds and uses thereof
|
US9512214B2
(en)
|
2012-09-02 |
2016-12-06 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
US9206390B2
(en)
|
2012-09-02 |
2015-12-08 |
Abbvie, Inc. |
Methods to control protein heterogeneity
|
EP2903691B1
(de)
|
2012-10-05 |
2019-05-22 |
F.Hoffmann-La Roche Ag |
Verfahren zur diagnose und behandlung von entzündlicher darmerkrankung
|
US10717965B2
(en)
|
2013-01-10 |
2020-07-21 |
Gloriana Therapeutics, Inc. |
Mammalian cell culture-produced neublastin antibodies
|
WO2014116749A1
(en)
|
2013-01-23 |
2014-07-31 |
Genentech, Inc. |
Anti-hcv antibodies and methods of using thereof
|
WO2014120891A2
(en)
|
2013-02-01 |
2014-08-07 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold proteins
|
WO2014143205A1
(en)
|
2013-03-12 |
2014-09-18 |
Abbvie Inc. |
Human antibodies that bind human tnf-alpha and methods of preparing the same
|
AR095398A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida
|
AU2014243700B2
(en)
|
2013-03-13 |
2019-01-24 |
Genentech, Inc. |
Formulations with reduced oxidation
|
JP6606059B2
(ja)
|
2013-03-13 |
2019-11-13 |
ジェネンテック, インコーポレイテッド |
酸化還元製剤
|
US20160152686A1
(en)
|
2013-03-13 |
2016-06-02 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domains linked to serum albumin or moiety binding thereto
|
CA2906057A1
(en)
|
2013-03-13 |
2014-10-02 |
Genentech, Inc. |
Antibody formulations
|
DK2968461T3
(da)
|
2013-03-13 |
2022-12-19 |
Genzyme Corp |
Fusionsproteiner, som omfatter pdgf- og vegf-bindende dele og fremgangsmåder til anvendelse deraf
|
AR095399A1
(es)
|
2013-03-13 |
2015-10-14 |
Genentech Inc |
Formulaciones con oxidación reducida, método
|
WO2014151878A2
(en)
|
2013-03-14 |
2014-09-25 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides
|
US9017687B1
(en)
|
2013-10-18 |
2015-04-28 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same using displacement chromatography
|
AU2013384204B2
(en)
|
2013-03-14 |
2017-03-16 |
Abbvie Inc. |
Low acidic species compositions and methods for producing and using the same
|
WO2014142882A1
(en)
|
2013-03-14 |
2014-09-18 |
Abbvie Inc. |
Protein purification using displacement chromatography
|
EP2970375A1
(de)
|
2013-03-14 |
2016-01-20 |
AbbVie Inc. |
Schwach saure zusammensetzungen und verfahren zu ihrer herstellung durch verdrängungschromatografie
|
AR095348A1
(es)
|
2013-03-15 |
2015-10-07 |
Genentech Inc |
Medios de cultivo celular y métodos de producción de anticuerpos
|
CN105121628B
(zh)
|
2013-03-15 |
2020-03-24 |
豪夫迈·罗氏有限公司 |
具有抗氧化剂的细胞培养组合物和多肽生产方法
|
CA2902288A1
(en)
|
2013-03-15 |
2014-09-18 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Use of tricarboxylic acid (tca) intermediates to control ammonia generation in cell culture
|
US20140283157A1
(en)
|
2013-03-15 |
2014-09-18 |
Diadexus, Inc. |
Lipoprotein-associated phospholipase a2 antibody compositions and methods of use
|
WO2014146575A1
(en)
|
2013-03-19 |
2014-09-25 |
Beijing Shenogen Pharma Group Ltd. |
Antibodies and methods for treating estrogen receptor-associated diseases
|
CA2904095A1
(en)
|
2013-03-27 |
2014-10-02 |
Genentech, Inc. |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
JP2016528192A
(ja)
|
2013-06-25 |
2016-09-15 |
セピア ペスキーサ イ デゼンボルビメント |
ブラジキニンの受容体のモジュレーターおよびその使用
|
WO2014210397A1
(en)
|
2013-06-26 |
2014-12-31 |
Academia Sinica |
Rm2 antigens and use thereof
|
US9981030B2
(en)
|
2013-06-27 |
2018-05-29 |
Academia Sinica |
Glycan conjugates and use thereof
|
EP3022224A2
(de)
|
2013-07-18 |
2016-05-25 |
Fabrus, Inc. |
Antikörper mit ultralangen komplementaritätsbestimmenden regionen
|
CN105814074B
(zh)
|
2013-07-18 |
2020-04-21 |
图鲁斯生物科学有限责任公司 |
具有超长互补决定区的人源化抗体
|
US20160237399A1
(en)
|
2015-02-18 |
2016-08-18 |
Biogen Ma Inc. |
Control of Protein Glycosylation by Culture Medium Supplementation and Cell Culture Process Parameters
|
EP3916081A3
(de)
|
2013-08-19 |
2022-03-23 |
Biogen MA Inc. |
Steuerung der proteinglykosylierung durch kulturmediumsupplementation und zellkulturprozessparameter
|
EP3039129B1
(de)
|
2013-08-30 |
2018-06-27 |
Amgen Inc. |
Herstellung rekombinanter aav-vektoren mit hohem titer in haftenden und hängenden zellen
|
US9782476B2
(en)
|
2013-09-06 |
2017-10-10 |
Academia Sinica |
Human iNKT cell activation using glycolipids with altered glycosyl groups
|
US10000744B2
(en)
|
2013-09-23 |
2018-06-19 |
Braskem S.A. |
Engineered enzyme having acetoacetyl-CoA hydrolase activity, microorganisms comprising same, and methods of using same
|
TWI714022B
(zh)
|
2013-09-27 |
2020-12-21 |
美商建南德克公司 |
抗-pdl1抗體調配物
|
WO2015051293A2
(en)
|
2013-10-04 |
2015-04-09 |
Abbvie, Inc. |
Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins
|
WO2015054427A1
(en)
|
2013-10-10 |
2015-04-16 |
Beth Israel Deaconess Medical Center, Inc. |
Tm4sf1 binding proteins and methods of using same
|
US9085618B2
(en)
|
2013-10-18 |
2015-07-21 |
Abbvie, Inc. |
Low acidic species compositions and methods for producing and using the same
|
US9181337B2
(en)
|
2013-10-18 |
2015-11-10 |
Abbvie, Inc. |
Modulated lysine variant species compositions and methods for producing and using the same
|
EP3066123A1
(de)
|
2013-11-07 |
2016-09-14 |
AbbVie Inc. |
Isolierung und reinigung von antikörpern
|
WO2015073884A2
(en)
|
2013-11-15 |
2015-05-21 |
Abbvie, Inc. |
Glycoengineered binding protein compositions
|
EP4389157A2
(de)
|
2013-11-15 |
2024-06-26 |
F. Hoffmann-La Roche AG |
Verfahren zur virusinaktivierung mit umweltfreundlichen waschmitteln
|
CA2930886C
(en)
|
2013-12-09 |
2024-05-21 |
Christopher R. Bebbington |
Anti-siglec-8 antibodies and methods of use thereof
|
MX2016007887A
(es)
|
2013-12-17 |
2016-10-28 |
Genentech Inc |
Metodos de tratamiento de canceres positivos a her2 usando antagonistas de union del eje de pd-1 y anticuerpos anti-her2.
|
SG11201604979WA
(en)
|
2013-12-17 |
2016-07-28 |
Genentech Inc |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
BR112016013741A2
(pt)
|
2013-12-17 |
2017-10-03 |
Genentech Inc |
Usos de antagonistas de ligação de eixo de pd-1 e um anticorpo de anti-cd20, e kit compreendendo os mesmos
|
JP2017500017A
(ja)
|
2013-12-20 |
2017-01-05 |
バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. |
生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用
|
WO2015109180A2
(en)
|
2014-01-16 |
2015-07-23 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10150818B2
(en)
|
2014-01-16 |
2018-12-11 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
WO2016114819A1
(en)
|
2015-01-16 |
2016-07-21 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
BR112016014731A2
(pt)
|
2014-01-31 |
2017-09-19 |
Boehringer Ingelheim Int |
Anticorpos anti-baff
|
WO2015116902A1
(en)
|
2014-01-31 |
2015-08-06 |
Genentech, Inc. |
G-protein coupled receptors in hedgehog signaling
|
WO2015120075A2
(en)
|
2014-02-04 |
2015-08-13 |
Genentech, Inc. |
Mutant smoothened and methods of using the same
|
EP4014995A1
(de)
|
2014-02-28 |
2022-06-22 |
Allakos Inc. |
Verfahren und zusammensetzungen zur behandlung von siglec-8-assoziierten krankheiten
|
US9738702B2
(en)
|
2014-03-14 |
2017-08-22 |
Janssen Biotech, Inc. |
Antibodies with improved half-life in ferrets
|
SG11201607820QA
(en)
|
2014-03-20 |
2016-10-28 |
Bristol Myers Squibb Co |
Serum albumin-binding fibronectin type iii domains
|
EP3647322B1
(de)
|
2014-03-20 |
2021-10-20 |
Bristol-Myers Squibb Company |
Stabilisierte fibronectinbasierte gerüstmoleküle
|
DK3122869T3
(da)
|
2014-03-24 |
2019-09-09 |
Biogen Ma Inc |
Fremgangsmåder til afhjælpning af glutamindeprivation under pattedyrecellekultur
|
RU2710551C2
(ru)
|
2014-03-25 |
2019-12-27 |
Дженентек, Инк. |
Способы приготовления полоксамера для применения в клеточной культуральной среде
|
TWI687428B
(zh)
|
2014-03-27 |
2020-03-11 |
中央研究院 |
反應性標記化合物及其用途
|
RU2016136716A
(ru)
|
2014-03-27 |
2018-04-28 |
Дженентек, Инк. |
Способы диагностики и лечения воспалительного заболевания кишечника
|
MX2016012779A
(es)
|
2014-03-31 |
2017-04-27 |
Genentech Inc |
Terapia de combinacion con agentes antiangiogénesis y agonistas de unión a ox40.
|
CA2943707A1
(en)
|
2014-05-06 |
2015-11-12 |
Genentech, Inc. |
Production of heteromultimeric proteins using mammalian cells
|
US10118969B2
(en)
|
2014-05-27 |
2018-11-06 |
Academia Sinica |
Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
|
JP7093612B2
(ja)
|
2014-05-27 |
2022-06-30 |
アカデミア シニカ |
Bacteroides由来のフコシダーゼおよびそれを使用する方法
|
CN106573971A
(zh)
|
2014-05-27 |
2017-04-19 |
中央研究院 |
抗cd20醣抗体及其用途
|
JP7062361B2
(ja)
|
2014-05-27 |
2022-05-06 |
アカデミア シニカ |
抗her2糖操作抗体群およびその使用
|
JP7063538B2
(ja)
|
2014-05-28 |
2022-05-09 |
アカデミア シニカ |
抗TNFα糖操作抗体群およびその使用
|
US11345908B2
(en)
|
2014-05-30 |
2022-05-31 |
Braskem S.A. |
Modified microorganisms comprising an optimized system for oligosaccharide utilization and methods of using same
|
EP3145951A1
(de)
|
2014-06-24 |
2017-03-29 |
InSight Biopharmaceuticals Ltd. |
Verfahren zur reinigung von antikörpern
|
WO2016004197A1
(en)
|
2014-07-03 |
2016-01-07 |
Abbvie Inc. |
Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using cobalt
|
PL3166401T3
(pl)
|
2014-07-09 |
2021-01-25 |
F. Hoffmann-La Roche Ag |
Dostosowanie pH w celu poprawy wyników regeneracji banków komórek po rozmrożeniu
|
US20160185848A1
(en)
|
2014-07-09 |
2016-06-30 |
Abbvie Inc. |
Methods for modulating the glycosylation profile of recombinant proteins using sugars
|
EP3708227A1
(de)
|
2014-07-22 |
2020-09-16 |
Sutro Biopharma, Inc. |
Anti-cd74-antikörper, zusammensetzungen mit anti-cd74-antikörpern und verfahren zur verwendung von anti-cd74-antikörpern
|
EP3708679A1
(de)
|
2014-07-24 |
2020-09-16 |
Boehringer Ingelheim International GmbH |
In der behandlung von il-23a-assoziierten erkrankungen nützlicher biomarker
|
AU2015315294B2
(en)
|
2014-09-08 |
2020-09-17 |
Academia Sinica |
Human iNKT cell activation using glycolipids
|
AU2015318008B2
(en)
|
2014-09-15 |
2021-05-20 |
Amgen Inc. |
Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereof
|
WO2016044334A1
(en)
|
2014-09-15 |
2016-03-24 |
Genentech, Inc. |
Antibody formulations
|
ES2854400T3
(es)
|
2014-10-13 |
2021-09-21 |
Univ Maryland |
Fc-ELA--32 y su uso en el tratamiento de afecciones cardiacas
|
ES2962385T3
(es)
|
2014-10-15 |
2024-03-18 |
Amgen Inc |
Elementos promotores y reguladores para mejorar la expresión de genes heterólogos en células hospederas
|
MA41685A
(fr)
|
2014-10-17 |
2017-08-22 |
Biogen Ma Inc |
Supplémentation en cuivre pour la régulation de la glycosylation dans un procédé de culture cellulaire de mammifère
|
MA40864A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Hypotaurine, gaba, bêta-alanine et choline pour la régulation de l'accumulation de sous-produits résiduaires dans des procédés de culture de cellules mammifères
|
CA2961439A1
(en)
|
2014-11-05 |
2016-05-12 |
Genentech, Inc. |
Anti-fgfr2/3 antibodies and methods using same
|
US20160166685A1
(en)
|
2014-11-17 |
2016-06-16 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
EP3221340B1
(de)
|
2014-11-19 |
2024-05-22 |
P & M Venge AB |
Diagnoseverfahren mit humanem neutrophilem lipocalin (hnl)
|
ES2764111T3
(es)
|
2014-12-03 |
2020-06-02 |
Hoffmann La Roche |
Anticuerpos multiespecíficos
|
US9975965B2
(en)
|
2015-01-16 |
2018-05-22 |
Academia Sinica |
Compositions and methods for treatment and detection of cancers
|
US10495645B2
(en)
|
2015-01-16 |
2019-12-03 |
Academia Sinica |
Cancer markers and methods of use thereof
|
AU2016209056B2
(en)
|
2015-01-24 |
2021-01-28 |
Academia Sinica |
Cancer markers and methods of use thereof
|
TWI736523B
(zh)
|
2015-01-24 |
2021-08-21 |
中央研究院 |
新穎聚醣結合物及其使用方法
|
EP3250590B1
(de)
|
2015-01-30 |
2021-09-15 |
Academia Sinica |
Zusammensetzungen und verfahren im zusammenhang mit universellen glykoformen für erhöhte anti-ssea4 antikörpereffizienz
|
IL307578A
(en)
|
2015-02-04 |
2023-12-01 |
Boehringer Ingelheim Int |
Methods for treating inflammatory diseases
|
AU2016215227A1
(en)
|
2015-02-04 |
2017-09-21 |
Assistance Publique-Hopitaux De Paris |
Mutant smoothened and methods of using the same
|
CN107257693A
(zh)
|
2015-02-26 |
2017-10-17 |
豪夫迈·罗氏有限公司 |
治疗Crohn病的整联蛋白β7拮抗剂和方法
|
WO2016141111A1
(en)
|
2015-03-03 |
2016-09-09 |
Xoma (Us) Llc |
Treatment of post-prandial hyperinsulinemia and hypoglycemia after bariatric surgery
|
JP6740244B2
(ja)
|
2015-03-31 |
2020-08-12 |
ノビミューン エスアー |
ヘテロ多量体タンパク質複合体のアセンブリおよび産生を最適化する方法
|
US10849992B1
(en)
|
2015-04-07 |
2020-12-01 |
Alector Llc |
Methods of screening for sortilin binding antagonists
|
IL254887B2
(en)
|
2015-04-07 |
2023-11-01 |
Alector Llc |
Anti-sortilin antibodies and methods of using them
|
EP3280736A1
(de)
|
2015-04-07 |
2018-02-14 |
F. Hoffmann-La Roche AG |
Antigenbindender komplexe mit agonistischer wirkung und verfahren zur verwendung
|
CN107530425A
(zh)
|
2015-04-14 |
2018-01-02 |
勃林格殷格翰国际有限公司 |
治疗疾病的方法
|
CN107787332B
(zh)
|
2015-04-24 |
2022-09-09 |
豪夫迈·罗氏有限公司 |
多特异性抗原结合蛋白
|
WO2016179518A2
(en)
|
2015-05-06 |
2016-11-10 |
Janssen Biotech, Inc. |
Prostate specific membrane antigen (psma) bispecific binding agents and uses thereof
|
AU2016271142A1
(en)
|
2015-05-29 |
2017-11-23 |
Genentech, Inc. |
PD-L1 promoter methylation in cancer
|
US10696745B2
(en)
|
2015-06-11 |
2020-06-30 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Anti-PD-L1 antibodies
|
WO2016197491A1
(en)
|
2015-06-12 |
2016-12-15 |
Institute Of Genetics And Developmental Biology, Chinese Academy Of Sciences |
A three-dimensional tissue scaffold with stem cell attracting element and use thereof
|
CA2987797A1
(en)
|
2015-06-17 |
2016-12-22 |
Christopher Robert Bebbington |
Methods and compositions for treating fibrotic diseases
|
CN107771076A
(zh)
|
2015-06-17 |
2018-03-06 |
豪夫迈·罗氏有限公司 |
使用pd‑1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
CN107849126B
(zh)
|
2015-07-29 |
2022-04-08 |
阿勒根公司 |
仅有重链的抗ang-2抗体
|
TW202340452A
(zh)
|
2015-08-04 |
2023-10-16 |
美商再生元醫藥公司 |
補充牛磺酸之細胞培養基及用法
|
WO2017020291A1
(en)
|
2015-08-06 |
2017-02-09 |
Wuxi Biologics (Shanghai) Co. Ltd. |
Novel anti-pd-l1 antibodies
|
JP2018532693A
(ja)
|
2015-08-06 |
2018-11-08 |
ゾーマ (ユーエス) リミテッド ライアビリティ カンパニー |
インスリン受容体に対する抗体断片及び低血糖を治療するためのその使用
|
EP3334763A4
(de)
|
2015-08-11 |
2019-04-03 |
Wuxi Biologics (Cayman) Inc. |
Neuartige anti-pd-1-antikörper
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
CA2992788A1
(en)
|
2015-08-14 |
2017-02-23 |
Allergan, Inc. |
Heavy chain only antibodies to pdgf
|
EP3341415B1
(de)
|
2015-08-28 |
2021-03-24 |
H. Hoffnabb-La Roche Ag |
Anti-hypusin-antikörper und verwendungen davon
|
KR20180050339A
(ko)
|
2015-09-04 |
2018-05-14 |
오비아이 파머 인코퍼레이티드 |
글리칸 어레이 및 사용 방법
|
MA42821A
(fr)
|
2015-09-15 |
2018-07-25 |
Amgen Inc |
Protéines de liaison à l'antigène tétraspécifiques et bispécifiques tétravalentes et utilisations de celles-ci
|
TWI733695B
(zh)
|
2015-09-18 |
2021-07-21 |
德商百靈佳殷格翰國際股份有限公司 |
治療發炎性疾病之方法
|
JP7010812B2
(ja)
|
2015-09-22 |
2022-02-10 |
ジェネンテック, インコーポレイテッド |
Fc含有タンパク質の発現
|
KR20180056701A
(ko)
|
2015-09-23 |
2018-05-29 |
브리스톨-마이어스 스큅 컴퍼니 |
패스트-오프 레이트 혈청 알부민 결합 피브로넥틴 유형 iii 도메인
|
CN108884147B
(zh)
|
2015-09-23 |
2024-02-27 |
百时美施贵宝公司 |
结合磷脂酰肌醇蛋白聚糖3的基于纤连蛋白的支架分子
|
US10604577B2
(en)
|
2015-10-22 |
2020-03-31 |
Allakos Inc. |
Methods and compositions for treating systemic mastocytosis
|
JP6983772B2
(ja)
|
2015-11-02 |
2021-12-17 |
ジェネンテック, インコーポレイテッド |
タンパク質のフコシル化及び脱フコシル化形態の作製方法
|
US20190330336A1
(en)
|
2015-11-19 |
2019-10-31 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
US10822408B2
(en)
|
2015-12-15 |
2020-11-03 |
Amgen Inc. |
PACAP antibodies and uses thereof
|
AU2016380988B2
(en)
|
2015-12-30 |
2022-07-21 |
Genentech, Inc. |
Formulations with reduced degradation of polysorbate
|
SG11201804951SA
(en)
|
2015-12-30 |
2018-07-30 |
Genentech Inc |
Use of tryptophan derivatives for protein formulations
|
WO2017118675A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
MX2018009085A
(es)
|
2016-01-27 |
2019-05-09 |
Sutro Biopharma Inc |
Conjugados de anticuerpos anti-cd74, composiciones que comprenden conjugados de anticuerpos anti-cd74 y metodos de uso de congujados de anticuerpos anti-cd74.
|
WO2017132376A1
(en)
|
2016-01-27 |
2017-08-03 |
Just Biotherapeutics, Inc. |
Hybrid promoter and uses thereof
|
AU2017213826A1
(en)
|
2016-02-04 |
2018-08-23 |
Curis, Inc. |
Mutant smoothened and methods of using the same
|
JP2019515876A
(ja)
|
2016-03-08 |
2019-06-13 |
アカデミア シニカAcademia Sinica |
N−グリカンおよびそのアレイのモジュール合成のための方法
|
CN109153719B
(zh)
|
2016-03-15 |
2022-12-30 |
中外制药株式会社 |
使用pd-1轴结合拮抗剂和抗gpc3抗体治疗癌症的方法
|
US10822416B2
(en)
|
2016-03-23 |
2020-11-03 |
Mabspace Biosciences (Suzhou) Co., Ltd |
Anti-PD-L1 antibodies
|
WO2017172990A1
(en)
|
2016-03-29 |
2017-10-05 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
US10980894B2
(en)
|
2016-03-29 |
2021-04-20 |
Obi Pharma, Inc. |
Antibodies, pharmaceutical compositions and methods
|
AU2017250807A1
(en)
|
2016-04-15 |
2018-10-25 |
H. Lundbeck A/S. |
Anti-PACAP antibodies and uses thereof
|
EP3974451A3
(de)
|
2016-04-15 |
2022-07-06 |
Boehringer Ingelheim International GmbH |
Verfahren zur behandlung von entzündlichen erkrankungen
|
IL262296B1
(en)
|
2016-04-22 |
2024-05-01 |
Obi Pharma Inc |
Cancer immunotherapy using immune activation or immune modulation by Globo-series antigens
|
CN114703244A
(zh)
|
2016-05-10 |
2022-07-05 |
豪夫迈·罗氏有限公司 |
重组产生多肽期间减少三硫键的方法
|
MA45186A
(fr)
*
|
2016-06-03 |
2019-04-10 |
Janssen Biotech Inc |
Domaines de fibronectine de type iii se liant à l'albumine sérique
|
WO2017218698A1
(en)
|
2016-06-15 |
2017-12-21 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
EP3472177A2
(de)
|
2016-06-17 |
2019-04-24 |
F. Hoffmann-La Roche AG |
Reinigung von multispezifischen antikörpern
|
WO2018014260A1
(en)
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
KR20230117482A
(ko)
|
2016-07-27 |
2023-08-08 |
오비아이 파머 인코퍼레이티드 |
면역원성/치료 글리칸 조성물 및 그의 용도
|
WO2018018613A1
(zh)
*
|
2016-07-29 |
2018-02-01 |
广东东阳光药业有限公司 |
一种提高抗体纯度的细胞培养基和培养方法
|
EP3491026A4
(de)
|
2016-07-29 |
2020-07-29 |
OBI Pharma, Inc. |
Menschliche antikörper, pharmazeutische zusammensetzungen und verfahren
|
WO2018027204A1
(en)
|
2016-08-05 |
2018-02-08 |
Genentech, Inc. |
Multivalent and multiepitopic anitibodies having agonistic activity and methods of use
|
EP3497129A1
(de)
|
2016-08-08 |
2019-06-19 |
H. Hoffnabb-La Roche Ag |
Therapeutische und diagnostische verfahren für krebs
|
US10538592B2
(en)
|
2016-08-22 |
2020-01-21 |
Cho Pharma, Inc. |
Antibodies, binding fragments, and methods of use
|
BR112019004711A2
(pt)
|
2016-09-14 |
2019-05-28 |
Janssen Biotech Inc |
receptores de antígeno quiméricos compreendendo domínios de fibronectina tipo iii específicos para bcma e usos dos mesmos
|
US11111313B2
(en)
|
2016-09-20 |
2021-09-07 |
WuXi Biologics Ireland Limited |
Anti-PCSK9 antibodies
|
JOP20190009A1
(ar)
|
2016-09-21 |
2019-01-27 |
Alx Oncology Inc |
أجسام مضادة ضد بروتين ألفا منظم للإشارات وطرق استخدامها
|
WO2018068201A1
(en)
|
2016-10-11 |
2018-04-19 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against ctla-4
|
WO2018071597A1
(en)
|
2016-10-12 |
2018-04-19 |
Sutro Biopharma, Inc. |
Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
|
US20180105588A1
(en)
|
2016-10-14 |
2018-04-19 |
Boehringer Ingelheim International Gmbh |
Methods of treating diseases
|
WO2018081649A1
(en)
|
2016-10-28 |
2018-05-03 |
Banyan Biomarkers, Inc. |
Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
|
CA3043528A1
(en)
|
2016-11-14 |
2018-05-17 |
Amgen Inc. |
Bispecific or biparatopic antigen binding proteins and uses thereof
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
AU2017361549B2
(en)
|
2016-11-21 |
2023-12-21 |
Obi Pharma, Inc. |
Conjugated biological molecules, pharmaceutical compositions and methods
|
CN109937034B
(zh)
|
2016-11-21 |
2022-09-16 |
济世-伊沃泰克生物制品有限公司 |
阿柏西普制剂及其用途
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
WO2018152496A1
(en)
|
2017-02-17 |
2018-08-23 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Compositions and methods for the diagnosis and treatment of zika virus infection
|
WO2018156785A1
(en)
|
2017-02-22 |
2018-08-30 |
Sutro Biopharma, Inc. |
Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
CN110753702B
(zh)
|
2017-03-15 |
2022-09-20 |
清华大学 |
抗trkb抗体
|
WO2018183173A1
(en)
|
2017-03-27 |
2018-10-04 |
Boehringer Ingelheim International Gmbh |
Anti il-36r antibodies combination therapy
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
JOP20190248A1
(ar)
|
2017-04-21 |
2019-10-20 |
Amgen Inc |
بروتينات ربط مولد ضد trem2 واستخداماته
|
EP3615569A1
(de)
|
2017-04-25 |
2020-03-04 |
The U.S.A. As Represented By The Secretary, Department Of Health And Human Services |
Antikörper und verfahren zur diagnose und behandlung von epstein-barr-virus-infektionen
|
JP2020518638A
(ja)
|
2017-05-05 |
2020-06-25 |
アラコス インコーポレイテッド |
アレルギー性眼疾患を処置するための方法および組成物
|
WO2018217940A2
(en)
|
2017-05-24 |
2018-11-29 |
Sutro Biopharma, Inc. |
Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
US10793634B2
(en)
|
2017-06-09 |
2020-10-06 |
Boehringer Ingelheim International Gmbh |
Anti-TrkB antibodies
|
KR20200028447A
(ko)
|
2017-07-17 |
2020-03-16 |
얀센 바이오테크 인코포레이티드 |
피브로넥틴 iii형 도메인에 대한 항원 결합 영역 및 이의 사용 방법
|
WO2019018629A1
(en)
|
2017-07-19 |
2019-01-24 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
ANTIBODIES AND METHODS FOR DIAGNOSING AND TREATING INFECTION WITH HEPATITIS B VIRUS
|
WO2019023316A1
(en)
|
2017-07-26 |
2019-01-31 |
Sutro Biopharma, Inc. |
METHODS OF USING ANTI-CD74 ANTIBODIES AND ANTIBODY CONJUGATES IN THE TREATMENT OF A T CELL LYMPHOMA
|
JP7122370B2
(ja)
|
2017-07-26 |
2022-08-19 |
フォーティ セブン, インコーポレイテッド |
抗sirp-アルファ抗体及び関連方法
|
EP3668985B1
(de)
|
2017-08-17 |
2021-06-16 |
Just-Evotec Biologics, Inc. |
Verfahren zur reinigung von glykosyliertem protein aus wirtszellen-galectinen und anderen verunreinigungen
|
US10596270B2
(en)
|
2017-09-18 |
2020-03-24 |
Sutro Biopharma, Inc. |
Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
|
JP2020536967A
(ja)
|
2017-10-12 |
2020-12-17 |
イミュノウェイク インコーポレイテッド |
Vegfr−抗体軽鎖融合タンパク質
|
CN111356471A
(zh)
|
2017-11-20 |
2020-06-30 |
济世发展生物药业有限公司 |
包含赖氨酸盐作为张力调节剂的阿柏西普制剂及其用途
|
US11905327B2
(en)
|
2017-12-28 |
2024-02-20 |
Nanjing Legend Biotech Co., Ltd. |
Single-domain antibodies and variants thereof against TIGIT
|
TWI831762B
(zh)
|
2018-01-12 |
2024-02-11 |
美商安進公司 |
Pac1抗體及其用途
|
CN111699200B
(zh)
|
2018-01-15 |
2023-05-26 |
南京传奇生物科技有限公司 |
针对pd-1的单域抗体和其变体
|
US11667949B2
(en)
|
2018-02-15 |
2023-06-06 |
The Trustees Of Princeton University |
Reporter construct and biosensor for interferon second messenger 2-5A
|
RU2020128013A
(ru)
|
2018-03-14 |
2022-04-15 |
Бейцзин Сюаньи Фармасайенсиз Ко., Лтд. |
Антитела против клаудина 18.2
|
WO2019179365A1
(en)
|
2018-03-20 |
2019-09-26 |
WuXi Biologics Ireland Limited |
Novel anti-lag-3 antibody polypeptide
|
MA52091A
(fr)
|
2018-03-21 |
2021-01-27 |
Alx Oncology Inc |
Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation
|
US11993658B2
(en)
|
2018-03-26 |
2024-05-28 |
Sutro Biopharma, Inc. |
Anti-BCMA antibodies and treatment methods
|
EP3775184A1
(de)
|
2018-03-29 |
2021-02-17 |
F. Hoffmann-La Roche AG |
Modulation der laktogenen aktivität bei säugerzellen
|
JP7346790B2
(ja)
|
2018-03-30 |
2023-09-20 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Lag‐3に対する単一ドメイン抗体およびその使用
|
JP2021519790A
(ja)
|
2018-04-02 |
2021-08-12 |
アムジェン インコーポレイテッド |
エレヌマブ組成物及びその使用
|
CN112334485A
(zh)
|
2018-04-06 |
2021-02-05 |
百进生物科技公司 |
抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
|
WO2019213416A1
(en)
|
2018-05-02 |
2019-11-07 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Antibodies and methods for the diagnosis, prevention, and treatment of epstein barr virus infection
|
AU2019271149B2
(en)
|
2018-05-14 |
2023-07-13 |
Werewolf Therapeutics, Inc. |
Activatable interleukin 12 polypeptides and methods of use thereof
|
BR112020023160A2
(pt)
|
2018-05-14 |
2021-02-02 |
Werewolf Therapeutics, Inc. |
polipeptídeos de interleucina 2 ativáveis e métodos de uso destes
|
KR20210024550A
(ko)
|
2018-06-23 |
2021-03-05 |
제넨테크, 인크. |
Pd-1 축 결합 길항제, 백금 제제, 및 토포이소머라제 ii 억제제를 이용한 폐암 치료 방법
|
US11203645B2
(en)
|
2018-06-27 |
2021-12-21 |
Obi Pharma, Inc. |
Glycosynthase variants for glycoprotein engineering and methods of use
|
CA3101469A1
(en)
|
2018-06-29 |
2020-01-02 |
Boehringer Ingelheim International Gmbh |
Anti-cd40 antibodies for use in treating autoimmune disease
|
LT3618928T
(lt)
|
2018-07-13 |
2023-04-11 |
Alector Llc |
Anti-sortilino antikūnai ir jų panaudojimo būdai
|
KR102140531B1
(ko)
|
2018-08-07 |
2020-08-04 |
(주)휴온스 |
Gly-Tβ4의 제조방법
|
KR20210042936A
(ko)
|
2018-08-08 |
2021-04-20 |
제넨테크, 인크. |
단백질 제제를 위한 트립토판 유도체 및 l-메티오닌의 용도
|
US20220047716A1
(en)
|
2018-09-17 |
2022-02-17 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
CA3111809A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
CA3113057A1
(en)
|
2018-09-21 |
2020-03-26 |
Teneobio, Inc. |
Methods for purifying heterodimeric, multispecific antibodies
|
CN113365697B
(zh)
|
2018-09-25 |
2024-07-19 |
百进生物科技公司 |
抗tlr9药剂和组合物及其制备方法和使用方法
|
BR112021005907A2
(pt)
|
2018-09-27 |
2021-08-10 |
Xilio Development, Inc. |
citocinas mascaradas, ácido nucleico, vetor, célula hospedeira, métodos para produzir uma citocina mascarada, para tratar ou prevenir uma doença neoplásica e para tratar ou prevenir uma doença inflamatória ou autoimune neoplásica, composição, composição farmacêutica e kit
|
EA202190609A1
(ru)
|
2018-09-27 |
2021-08-17 |
Тизона Терапьютикс |
Антитела против hla-g, композиции, содержащие антитела против hla-g, и способы применения антител против hla-g
|
SG11202103124WA
(en)
|
2018-10-23 |
2021-04-29 |
Glycardial Diagnostics S L |
Antibodies specific for glycosylated apoj and uses thereof
|
WO2020086408A1
(en)
|
2018-10-26 |
2020-04-30 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
A high-yield perfusion-based transient gene expression bioprocess
|
HUP1800376A2
(hu)
|
2018-11-07 |
2020-05-28 |
Richter Gedeon Nyrt |
Sejttenyészetben elõállított rekombináns glikoprotein glikozilációs-mintázatának megváltoztatására szolgáló módszer
|
EP3898984A1
(de)
|
2018-12-21 |
2021-10-27 |
Genentech, Inc. |
Verfahren zur herstellung von polypeptiden unter verwendung einer gegen apoptose resistenten zelllinie
|
CA3123050A1
(en)
|
2018-12-26 |
2020-07-02 |
City Of Hope |
Activatable masked anti-ctla4 binding proteins
|
KR20210118115A
(ko)
|
2019-01-23 |
2021-09-29 |
제넨테크, 인크. |
진핵 숙주 세포에서 다합체 단백질을 생산하는 방법
|
AU2020223376A1
(en)
|
2019-02-15 |
2021-07-22 |
Just - Evotec Biologics, Inc. |
Automated biomanufacturing systems, facilities, and processes
|
EA202192405A1
(ru)
|
2019-03-08 |
2022-01-13 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Составы антител против il-36r
|
JPWO2020213724A1
(de)
|
2019-04-19 |
2020-10-22 |
|
|
US20220362394A1
(en)
|
2019-05-03 |
2022-11-17 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
WO2020227110A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same
|
CR20210559A
(es)
|
2019-05-09 |
2021-12-23 |
Boehringer Ingelheim Int |
Anticuerpos anti-sema3a y sus usos para tratar enfermedades oculares
|
EP3966244A1
(de)
|
2019-05-09 |
2022-03-16 |
F. Hoffmann-La Roche AG |
Verfahren zur herstellung von antikörpern
|
BR112021022666A2
(pt)
|
2019-05-14 |
2022-03-29 |
Werewolf Therapeutics Inc |
Frações de separação e seus métodos e uso
|
EP3978532A4
(de)
|
2019-05-24 |
2023-10-18 |
Sanyou Biopharmaceuticals Co., Ltd. |
Neue cldn18.2-bindende moleküle
|
TW202110877A
(zh)
|
2019-05-30 |
2021-03-16 |
美商安進公司 |
工程改造鉸鏈區以驅動抗體二聚化
|
EP3980423A1
(de)
|
2019-06-10 |
2022-04-13 |
Sutro Biopharma, Inc. |
5h-pyrrolo[3,2-d]pyrimidin-2,4-diaminverbindungen und ihre antikörper-konjugate
|
WO2020257235A1
(en)
|
2019-06-17 |
2020-12-24 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
TW202115112A
(zh)
|
2019-06-27 |
2021-04-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗-angpt2抗體
|
CA3143524A1
(en)
|
2019-06-28 |
2020-12-30 |
Amgen Inc. |
Anti-cgrp receptor/anti-pac1 receptor bispecific antigen binding proteins
|
US20220267452A1
(en)
|
2019-07-12 |
2022-08-25 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-mutation type fgfr3 antibody and use therefor
|
BR112021005478A2
(pt)
|
2019-07-24 |
2021-06-15 |
H. Lundbeck A/S |
anticorpos anti-mglur5 e uso dos mesmos
|
TW202126685A
(zh)
|
2019-09-24 |
2021-07-16 |
德商百靈佳殷格翰國際股份有限公司 |
抗nrp1a抗體及其用於治療眼或眼部疾病之用途
|
TW202132340A
(zh)
|
2019-11-04 |
2021-09-01 |
美商安進公司 |
治療白血病之方法
|
AU2020380379A1
(en)
|
2019-11-08 |
2022-05-26 |
Amgen Inc. |
Engineering charge pair mutations for pairing of hetero-IgG molecules
|
AU2020384375A1
(en)
|
2019-11-14 |
2022-05-26 |
Werewolf Therapeutics, Inc. |
Activatable cytokine polypeptides and methods of use thereof
|
WO2021102049A1
(en)
|
2019-11-19 |
2021-05-27 |
Amgen Inc. |
Novel multispecific antibody format
|
IL293640A
(en)
|
2019-12-20 |
2022-08-01 |
Amgen Inc |
CD40 antagonistic mesothelin-targeted multispecific antibody constructs for the treatment of solid tumors
|
CN115427447A
(zh)
|
2020-01-17 |
2022-12-02 |
百进生物科技公司 |
抗tlr7药剂和组合物以及制备和使用其的方法
|
WO2023172491A1
(en)
|
2022-03-07 |
2023-09-14 |
Ultragenyx Pharmaceutical Inc. |
Modified batch aav production systems and methods
|
US20210261987A1
(en)
|
2020-02-21 |
2021-08-26 |
Braskem S.A. |
Production of ethanol with one or more co-products in yeast
|
US11365239B2
(en)
|
2020-03-20 |
2022-06-21 |
Tsb Therapeutics (Beijing) Co., Ltd. |
Anti-SARS-COV-2 antibodies and uses thereof
|
EP4127153A2
(de)
|
2020-03-26 |
2023-02-08 |
Genentech, Inc. |
Modifizierte säugetierzellen mit reduzierten wirtszellproteinen
|
US20210371809A1
(en)
|
2020-04-15 |
2021-12-02 |
Genentech, Inc. |
Copper loss mitigation
|
BR112022021203A2
(pt)
|
2020-04-24 |
2022-12-06 |
Hoffmann La Roche |
Modulação de enzima e via com compostos sulfidrila e seus derivados
|
CR20220596A
(es)
|
2020-05-26 |
2023-01-23 |
Boehringer Ingelheim Int |
Anticuerpos anti-pd-1
|
MX2022015877A
(es)
|
2020-06-16 |
2023-01-24 |
Genentech Inc |
Metodos y composiciones para tratar cancer de mama triple negativo.
|
WO2021262783A1
(en)
|
2020-06-24 |
2021-12-30 |
Genentech, Inc. |
Apoptosis resistant cell lines
|
EP4200338A1
(de)
|
2020-08-20 |
2023-06-28 |
Amgen Inc. |
Antigenbindende proteine mit nichtkanonischem disulfid in der fab-region
|
CA3192344A1
(en)
|
2020-08-28 |
2022-03-03 |
Genentech, Inc. |
Crispr/cas9 multiplex knockout of host cell proteins
|
WO2022060878A1
(en)
|
2020-09-16 |
2022-03-24 |
Amgen Inc. |
Methods for treating prostate cancer
|
MX2023003041A
(es)
|
2020-09-16 |
2023-05-09 |
Amgen Inc |
Métodos para administrar dosis terapéuticas de moléculas de acoplamiento a células t biespecíficas para el tratamiento de cáncer.
|
JP2023544769A
(ja)
|
2020-10-07 |
2023-10-25 |
アムジエン・インコーポレーテツド |
多重特異性抗体の構築のためのビルディングブロックの合理的選択
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
WO2022103773A1
(en)
|
2020-11-10 |
2022-05-19 |
Amgen Inc. |
Novel linkers of multispecific antigen binding domains
|
CN112480248B
(zh)
|
2020-11-24 |
2023-05-05 |
三优生物医药(上海)有限公司 |
与cld18a2特异性结合的分子
|
CN112538458A
(zh)
|
2020-11-26 |
2021-03-23 |
北京赛尔湃腾科技咨询合伙企业(有限合伙) |
用于重编程细胞的方法
|
CN117043181A
(zh)
|
2020-12-18 |
2023-11-10 |
基尼科萨制药有限公司 |
蛋白质组合物以及其产生和使用方法
|
WO2022140797A1
(en)
|
2020-12-23 |
2022-06-30 |
Immunowake Inc. |
Immunocytokines and uses thereof
|
WO2022165001A1
(en)
|
2021-01-29 |
2022-08-04 |
Merck Sharp & Dohme Llc |
Compositions of programmed death receptor 1 (pd-1) antibodies and methods of obtaining the compositions thereof
|
CN117062836A
(zh)
|
2021-02-05 |
2023-11-14 |
勃林格殷格翰国际有限公司 |
抗il1rap抗体
|
CA3209364A1
(en)
|
2021-03-01 |
2022-09-09 |
Jennifer O'neil |
Combination of masked ctla4 and pd1/pdl1 antibodies for treating cancer
|
US20220306743A1
(en)
|
2021-03-01 |
2022-09-29 |
Xilio Development, Inc. |
Combination of ctla4 and pd1/pdl1 antibodies for treating cancer
|
AU2022232951A1
(en)
|
2021-03-10 |
2023-10-19 |
Immunowake Inc. |
Immunomodulatory molecules and uses thereof
|
IL307501A
(en)
|
2021-04-19 |
2023-12-01 |
Hoffmann La Roche |
Modified mammalian cells
|
JP2024515301A
(ja)
|
2021-04-20 |
2024-04-08 |
アムジエン・インコーポレーテツド |
多重特異性及び一価のigg分子の会合における鎖対形成の静電ステアリングにおけるバランスのとれた電荷分布
|
BR112023021867A2
(pt)
|
2021-04-23 |
2023-12-19 |
Amgen Inc |
Composições de anticorpo anti-tslp e seus usos
|
EP4332120A1
(de)
|
2021-04-26 |
2024-03-06 |
Xuanzhu Biopharmaceutical Co., Ltd. |
Bispezifisches antikörper-wirkstoff-konjugat
|
US11931420B2
(en)
|
2021-04-30 |
2024-03-19 |
Celgene Corporation |
Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI)
|
EP4340876A1
(de)
|
2021-05-19 |
2024-03-27 |
Sutro Biopharma, Inc. |
Kombinationstherapie mit anti-folat-rezeptorkonjugaten mit bevacizumab
|
CN117396599A
(zh)
|
2021-05-21 |
2024-01-12 |
基因泰克公司 |
用于生产目的重组产物的经修饰的细胞
|
AU2022283289A1
(en)
|
2021-05-27 |
2023-12-07 |
R.P. Scherer Technologies, Llc |
Methods of controlling cleavage of formylglycine-containing polypeptides
|
EP4370647A1
(de)
|
2021-07-15 |
2024-05-22 |
Just-Evotec Biologics, Inc. |
Bidirektionales perfusionssystem mit tangentialer strömungsfiltration (tff)
|
WO2023028501A1
(en)
|
2021-08-23 |
2023-03-02 |
Immunitas Therapeutics, Inc. |
Anti-cd161 antibodies and uses thereof
|
WO2023086910A1
(en)
|
2021-11-12 |
2023-05-19 |
Genentech, Inc. |
Methods of treating crohn's disease using integrin beta7 antagonists
|
WO2023092324A1
(zh)
|
2021-11-24 |
2023-06-01 |
苏州光度生物科技有限公司 |
多特异性配体结合分子及其应用
|
AU2022402850A1
(en)
|
2021-12-01 |
2024-06-06 |
Sutro Biopharma, Inc. |
Anti-folate receptor conjugate cancer therapy
|
WO2023114897A2
(en)
|
2021-12-15 |
2023-06-22 |
Homology Medicines, Inc. |
Methods and compositions for the production of adeno-associated virus
|
AR128065A1
(es)
|
2021-12-22 |
2024-03-20 |
Cdr Life Ag |
Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares
|
AR128222A1
(es)
|
2022-01-07 |
2024-04-10 |
Johnson & Johnson Entpr Innovation Inc |
MATERIALES Y MÉTODOS DE PROTEÍNAS DE UNIÓN A IL-1b
|
WO2023154305A2
(en)
|
2022-02-10 |
2023-08-17 |
Amgen Inc. |
Antibody protein product expression constructs for high throughput sequencing
|
WO2023172903A1
(en)
|
2022-03-08 |
2023-09-14 |
Amgen Inc. |
Modular vector (modvec) system: a platform for construction of next generation expression vectors
|
WO2023172965A1
(en)
|
2022-03-09 |
2023-09-14 |
Amgen Inc. |
Optimized transfection protocol
|
WO2023183231A1
(en)
|
2022-03-21 |
2023-09-28 |
Amgen Inc. |
Combination therapy methods with t-cell engaging molecules for treatment of prostate cancer
|
WO2024006563A1
(en)
|
2022-07-01 |
2024-01-04 |
Sutro Biopharma, Inc. |
Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
US20240067994A1
(en)
|
2022-08-24 |
2024-02-29 |
Braskem S.A. |
Process for the recovery of low-boiling point components from an ethanol stream
|
WO2024044780A1
(en)
|
2022-08-26 |
2024-02-29 |
Sutro Biopharma, Inc. |
Interleukin-18 variants and uses thereof
|
WO2024077044A1
(en)
|
2022-10-05 |
2024-04-11 |
Amgen Inc. |
Combination therapies comprising t-cell redirecting therapies and agonistic anti-il-2r antibodies or fragments thereof
|
WO2024092064A1
(en)
|
2022-10-26 |
2024-05-02 |
Amgen Inc. |
Anti-tslp antibody compositions and uses thereof
|
WO2024098023A2
(en)
|
2022-11-04 |
2024-05-10 |
Sutro Biopharma, Inc. |
Interferon alpha polypeptides and conjugates
|